Author

Adam Foley‐Comer

Observed names: A. Foley-Comer, Adam Foley-Comer, Adam J Foley-Comer, Adam J. Foley-Comer, Foley-Comer, Adam

Observed institutions: University of Groningen, Hadassah Medical Center, The Royal Free Hospital, Roche (United Kingdom), BioLineRx Ltd. (Israel), University College London

OpenAlex ID: A5041985338

Evidence for incorporation of free-floating mesothelial cells as a mechanism of serosal healing

2002 · Adam J. Foley-Comer, Sarah E. Herrick, et al. · Journal of Cell Science · 150

HGF/SF Induces Mesothelial Cell Migration and Proliferation by Autocrine and Paracrine Pathways

2001 · Richard Warn, Pascale Harvey, et al. · Experimental Cell Research · 58

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

2020 · Gautam Borthakur, Yishai Ofran, et al. · Cancer · 43

PDF

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

2022 · Ewa Cendrowicz, Lisa Jacob, et al. · Journal of Experimental & Clinical Cancer Research · 27

PDF

BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial

2014 · Gautam Borthakur, Arnon Nagler, et al. · Blood · 14

Abstract A076: DSP107—a novel SIRPα-4-1BBL dual signaling protein (DSP) for cancer immunotherapy

2019 · Yosi M. Gozlan, Susan Hilgendorf, et al. · Cancer Immunology Research · 10

DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

2020 · Ewa Cendrowicz, Lisa Jacob, et al. · Blood · 8

Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin

2010 · Adam J Foley-Comer, Anne-Marie Young, et al. · Expert Opinion on Investigational Drugs · 7

Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein, in patients with advanced solid tumors.

2022 · Jason J. Luke, Anwaar Saeed, et al. · Journal of Clinical Oncology · 5

Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.

2025 · Anwaar Saeed, Jun Zhang, et al. · Journal of Clinical Oncology · 4

51P Phase II dose expansion study of DSP107, a first-in-class fusion protein targeting CD47 and 4-1BB, in combination with atezolizumab in patients with advanced MSS colorectal cancer

2024 · A. Saeed, J. Zhang, et al. · Annals of Oncology · 2

PDF

Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.

2023 · Anwaar Saeed, Babar Bashir, et al. · Journal of Clinical Oncology · 2

PDF

Additional file 1 of DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

2022 · Cendrowicz, Ewa, Jacob, Lisa, et al. · Figshare

790 DSP502 — A novel approach for targeting TIGIT and PD1 pathways for cancer immunotherapy

2021 · Ayelet Chajut, Shirley Greenwald, et al. · Regular and Young Investigator Award Abstracts

PDF

DSP107-A first in class, bifunctional fusion protein targeting both innate and adaptive immunity

2019 · Adam Foley‐Comer, Shirley Greenwald, et al. · University of Groningen research database (University of Groningen / Centre for Information Technology)

No Clinically Relevant Drug-Drug Interactions Between Dalcetrapib and a Monophasic Oral Contraceptive (Microgynon-30®)

2010 · Anne-Marie Young, Adam Foley-Comer, et al. · Journal of clinical lipidology

Works count: 17

Citation count: 330

H-index: 7

I10-index: 6